A vial of a plant-derived COVID-19 vaccine candidate, developed by Medicago, is shown in Quebec City on Monday, July 13, 2020 as part of the company’s Phase 1 clinical trials in this handout photo. Medicago says it has received promising early test results for its plant-derived vaccine for COVID-19. THE CANADIAN PRESS/HO, Medicago

A vial of a plant-derived COVID-19 vaccine candidate, developed by Medicago, is shown in Quebec City on Monday, July 13, 2020 as part of the company’s Phase 1 clinical trials in this handout photo. Medicago says it has received promising early test results for its plant-derived vaccine for COVID-19. THE CANADIAN PRESS/HO, Medicago

Canadian company reports promising early Phase 1 test results of possible COVID-19 vaccine

Quebec City-based company says the side-effects were generally mild to moderate and short in duration

A Canadian biopharmaceutical company says it has received promising early test results for its plant-derived vaccine for COVID-19.

Privately held Medicago says interim results of a Phase 1 clinical trial found that 100 per cent of subjects developed an antibody response after two doses of its COVID-19 vaccine candidate.

“These are very promising results,” said Nathalie Landry, Medicago’s executive vice-president of scientific and medical affairs in a news release.

“We also observed that the antibody levels were higher after vaccination than those observed in convalescent sera from people who recovered from the disease.”

The Quebec City-based company says the side-effects were generally mild to moderate and short in duration.

The Phase 1 clinical trial was a randomized, partially blinded study of 180 healthy people.

Based on the Phase 1 data, Medicago plans to proceed with a Phase 2/3 clinical trial for its COVID-19 vaccine candidate, subject to regulatory approval.

The news comes a day after stock markets worldwide rallied on a report from Pfizer that a potential COVID-19 vaccine it’s developing with German partner BioNTech may be 90 per cent effective, based on early but incomplete test results.

“The positive results of our Phase 1 clinical trial are a step forward in the fight against the COVID-19 pandemic and we are confidently moving forward to our Phase 2/3 trial. We’re pleased that Medicago’s innovative manufacturing technology is helping to diversify the classes of COVID-19 vaccines candidates in development,” said CEO Dr. Bruce Clark.

The federal government has signed a deal with Medicago to secure the rights to buy 76 million doses of its vaccine.

VIDEO: Trudeau says he hopes to see COVID-19 vaccines roll out in Canada in early 2021

Medicago will also receive $173 million in funding from Ottawa for its vaccine research and development and for the construction of its Quebec City manufacturing facility.

Ottawa is also investing $18.2 million in a potential vaccine from British Columbia’s Precision NanoSystems and the National Research Council is to spend $23 million to support other Canadian vaccine initiatives.

Medicago was founded in 1999 and says its team includes over 450 scientific experts and employees in Canada and the United States, with academic affiliations in Europe and South Africa.

The Canadian Press


Like us on Facebook and follow us on Twitter.

Want to support local journalism during the pandemic? Make a donation here.

Coronavirusvaccines

Get local stories you won't find anywhere else right to your inbox.
Sign up here

Just Posted

(Photo submitted)
Bentley couple celebrates 60th anniversary

They still laugh, hold hands, play crib and fish says daughter

Alberta’s chief medical officer of health, Dr. Deena Hinshaw, announced the province surpasses one million COVID-19 tests Friday. (Photo by Chris Schwarz/Government of Alberta)
COVID-19: Central zone active cases up by 100 in last 24 hours

Most central Alberta communities under province’s enhanced measures list

.
Alberta confirmed more than 1,500 COVID-19 cases Sunday

Central zone active cases slightly up

A nurse gets a swab ready at a temporary COVID-19 test clinic in Montreal, on Friday, May 15, 2020. Health Canada has reversed course on home test kits for COVID-19, saying it will now review applications for such devices. THE CANADIAN PRESS/Paul Chiasson
Kyle Charles poses for a photo in Edmonton on Friday, Nov. 20, 2020. Marvel Entertainment, the biggest comic book publisher in the world, hired the 34-year-old First Nations illustrator as one of the artists involved in Marvel Voice: Indigenous Voices #1 in August. THE CANADIAN PRESS/Jason Franson
VIDEO: Indigenous illustrator of new Marvel comic hopes Aboriginal women feel inspired

Kyle Charles says Indigenous women around the world have reached out

Russ and Luanne Carl are sharing about their experiences of fighting COVID-19 this past summer. (Photo submitted)
Stettler couple opens up about COVID-19 battle

Luanne and Russ Carl urge others to bolster personal safety measures amidst ongoing pandemic

Prime Minister Justin Trudeau speak to the media about the COVID-19 virus outside Rideau Cottage in Ottawa, Friday, Nov. 20, 2020. THE CANADIAN PRESS/Adrian Wyld
Canada’s inability to manufacture vaccines in-house will delay distribution: Trudeau

First doses of COVID-19 vaccine expected in first few months of 2021, prime minister says

This undated photo issued by the University of Oxford shows of vial of coronavirus vaccine developed by AstraZeneca and Oxford University, in Oxford, England. Pharmaceutical company AstraZeneca said Monday Nov. 23, 2020, that late-stage trials showed its coronavirus vaccine was up to 90% effective, giving public health officials hope they may soon have access to a vaccine that is cheaper and easier to distribute than some of its rivals. (University of Oxford/John Cairns via AP)
VIDEO: How do the leading COVID vaccines differ? And what does that mean for Canada?

All three of the drug companies are incorporating novel techniques in developing their vaccines

Ilaria Rubino is shown in this undated handout image at University of Alberta. Alberta researcher Rubino has developed technology allowing mostly salt to kill pathogens in COVID-19 droplets as they land on a mask. THE CANADIAN PRESS/HO-University of Alberta
Alberta researcher gets award for COVID-19 mask innovation

The salt-coated mask is expected to be available commercially next year after regulatory approval.

This 2019 photo provided by The ALS Association shows Pat Quinn. Quinn, a co-founder of the viral ice bucket challenge, died Sunday, Nov. 22, 2020, at the age of 37. (Scott Kauffman/The ALS Association via AP)
Co-founder of viral ALS Ice Bucket Challenge dies at 37

Pat Quinn was diagnosed with Lou Gehrig’s disease, also known as amyotrophic lateral sclerosis, in 2013

Minister of Justice and Attorney General of Canada David Lametti speaks with the media following party caucus in Ottawa, Tuesday, January 28, 2020. THE CANADIAN PRESS/Adrian Wyld
Exclusion of mental health as grounds for assisted death is likely temporary: Lametti

Senators also suggested the exclusion renders the bill unconstitutional

Claudio Mastronardi, Toronto branch manager at Carmichael Engineering, is photographed at the company’s offices in Mississauga, Ont., Thursday, Nov. 19, 2020. As indoor air quality becomes a major concern in places of business, HVAC companies are struggling to keep up with demand for high quality filtration systems. THE CANADIAN PRESS/Chris Young
Business is booming for HVAC companies as commercial buildings see pandemic upgrades

‘The demand right now is very high. People are putting their health and safety ahead of cost’

Prime Minister Justin Trudeau speak to the media about the COVID-19 virus outside Rideau Cottage in Ottawa, Friday, Nov. 20, 2020. THE CANADIAN PRESS/Adrian Wyld
Long-awaited federal rent subsidy program for businesses hurt by COVID-19 opens today

The new program will cover up to 65 per cent of rent or commercial mortgage interest

Most Read